Cue Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 28, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 28, 2024
CUE$18.76-6.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at December 31, 2023 and 2022
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $48,514 | $51,614 |
| Marketable securities | — | 24,675 |
| Accounts receivable | 1,698 | 57 |
| Prepaid expenses and other current assets | 1,242 | 841 |
| Total current assets | 51,454 | 77,187 |
| Property and equipment, net | 795 | 1,499 |
| Operating lease right-of-use asset | 6,323 | 9,203 |
| Deposits | 2,690 | 3,116 |
| Restricted cash | 151 | 150 |
| Other long term assets | 117 | 128 |
| Total assets | $61,530 | $91,283 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $3,501 | $2,731 |
| Accrued expenses | 4,137 | 3,554 |
| Research and development contract liability, current portion | 2,112 | — |
| Operating lease liabilities, current portion | 3,368 | 3,300 |
| Current portion of long-term debt, net | 3,963 | 1,963 |
| Total current liabilities | 17,081 | 11,548 |
| Operating lease liabilities, net of current portion | 3,162 | 6,018 |
| Long-term debt, net | 4,202 | 8,035 |
| Total liabilities | $24,445 | $25,601 |
| Commitments and contingencies (Note 15) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, authorized – 10,000,000 shares; issued and outstanding – none | — | — |
| Common stock, $0.001 par value; authorized – 100,000,000 shares; issued and outstanding – 47,215,116 shares and 43,042,548 shares at December 31, 2023 and 2022, respectively | 47 | 43 |
| Additional paid-in capital | 338,228 | 316,192 |
| Accumulated other comprehensive income (loss) | — | (96) |
| Accumulated deficit | (301,190) | (250,457) |
| Total stockholders’ equity | 37,085 | 65,682 |
| Total liabilities and stockholders’ equity | $61,530 | $91,283 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.